Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors

J. K. Hicks, J. R. Bishop, K. Sangkuhl, D. J. Muller, Y. Ji, S. G. Leckband, J. S. Leeder, R. L. Graham, D. L. Chiulli, A. LLerena, T. C. Skaar, S. A. Scott, J. C. Stingl, T. E. Klein, K. E. Caudle, A. Gaedigk

Research output: Contribution to journalArticlepeer-review

347 Scopus citations

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).

Original languageEnglish (US)
Pages (from-to)127-134
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume98
Issue number2
DOIs
StatePublished - Aug 1 2015

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors'. Together they form a unique fingerprint.

Cite this